Department of Physio and Occupational Therapy, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark.
Department of Orthopaedic Surgery, Aalborg University Hospital, Aalborg, Denmark.
Knee Surg Sports Traumatol Arthrosc. 2018 Jul;26(7):2038-2044. doi: 10.1007/s00167-017-4675-7. Epub 2017 Aug 30.
Polidocanol injections have been used to treat chronic Achilles tendinopathy in clinical settings, but the few studies published show inconsistent results. The aim of this study was to evaluate the mid-term effect of Polidocanol in patients with chronic Achilles tendinopathy. It was hypothesised that patients treated with Polidocanol would have significant improvements in the outcome measures investigated compared to patients treated with a placebo treatment at mid-term follow-up.
This randomised controlled trial included forty-eight patients aged 32-77 years with a history of Achilles tendinopathy for at least 3 months and with neovascularisation demonstrated by ultrasonography was included. A minimum of 3 months of eccentric exercise treatment was required before participating. The patients were allocated to a maximum of two injection of either Polidocanol or Lidocaine (placebo). The primary outcome measure was pain during walking reported on a visual analogue scale. Secondary outcome measures were Foot and Ankle Outcome Score (FAOS), patient satisfaction with treatment and, shortly after inclusion, the Victorian Institute of Sports Assessment-Achilles questionnaire (VISA-A) was also included. Follow-up examinations were performed after 3 and 6 months.
Pain during walking decreased during the 6-month follow-up period, but no significant differences were seen between the two groups. The same tendency was seen for FAOS and VISA-A in which both groups showed an improvement at 3- and 6-month follow-up, but no mid-term differences between the groups were seen. An equal number of patients in the two groups were satisfied with the treatment at follow-up.
The results indicate that Polidocanol is a safe treatment, but the mid-term effects are the same as a placebo treatment. This further questions the use of Polidocanol in the treatment of chronic Achilles tendinopathy.
I.
聚多卡醇注射已被用于临床治疗慢性跟腱病，但少数已发表的研究结果不一致。本研究旨在评估聚多卡醇治疗慢性跟腱病的中期疗效。假设与安慰剂治疗组相比，接受聚多卡醇治疗的患者在中期随访时，调查结果的指标将有显著改善。
这项随机对照试验纳入了 48 名年龄在 32-77 岁之间的患者，这些患者都有至少 3 个月的跟腱病病史，且超声显示有新生血管形成。在参与研究之前，至少需要 3 个月的离心运动治疗。患者被分配到最多接受两次聚多卡醇或利多卡因（安慰剂）注射。主要观察指标为视觉模拟评分法（VAS）评估的行走时疼痛。次要观察指标为足踝外科结果评分（FAOS）、患者对治疗的满意度以及在纳入后不久的维多利亚运动评估-跟腱问卷（VISA-A）。随访检查在 3 个月和 6 个月时进行。
在 6 个月的随访期间，行走时的疼痛有所减轻，但两组之间没有显著差异。FAOS 和 VISA-A 也有同样的趋势，两组在 3 个月和 6 个月的随访时都有改善，但两组之间没有中期差异。两组患者在随访时对治疗的满意度相同。
结果表明，聚多卡醇是一种安全的治疗方法，但中期疗效与安慰剂治疗相同。这进一步质疑了聚多卡醇在慢性跟腱病治疗中的应用。
I。
